Report cover image

Gastroparesis Drugs Market – By Drug Class (Prokinetic Agents, Proton Pump Inhibitor), Disease Type (Idiopathic Gastroparesis), Route of Administration (Oral, Injectable), Drug Type (OTC, Prescription), Distribution Channel (Retail Pharmacies, Online) – G

Publisher Global Market Insights
Published May 02, 2024
Length 182 Pages
SKU # GMI19055282

Description

Gastroparesis Drugs Market – By Drug Class (Prokinetic Agents, Proton Pump Inhibitor), Disease Type (Idiopathic Gastroparesis), Route of Administration (Oral, Injectable), Drug Type (OTC, Prescription), Distribution Channel (Retail Pharmacies, Online) – Global Forecast (2024 – 2032)


Global Gastroparesis Drugs Market will register over 5% CAGR from 2024 to 2032. The market is expanding due to significant investments by pharmaceutical companies in research and development. This investment aims to meet the unmet medical needs of patients suffering from gastroparesis, a condition characterized by delayed stomach emptying.

With advancements in drug development and therapeutic strategies, pharmaceutical firms are focusing on innovative treatments to improve patient outcomes. These efforts not only usher market growth but also enhance the availability of effective medications for managing gastroparesis, catering to the increasing demand driven by rising disease prevalence and diagnostic advancements globally.

The overall Gastroparesis Drugs industry is classified based on drug class, disease type, route of administration, drug type, distribution channel, and region.

The pro kinetic agents segment in the gastroparesis drugs market will maintain a notable CAGR between 2024 and 2032, owing to their effectiveness in enhancing stomach motility, a critical therapeutic target for managing gastroparesis symptoms. pro kinetic agents stimulate gastrointestinal contractions, thus promoting more timely stomach emptying and alleviating symptoms such as nausea, vomiting, and bloating. As pharmaceutical companies focus on developing and improving these agents, patients and healthcare providers increasingly rely on them for symptom relief and improved quality of life. This targeted approach underscores the growing demand for specialized treatments within the market, driving advancements in pro-kinetic therapies.

By 2032, the idiopathic gastroparesis sector will secure a significant gastroparesis drugs market share because of its status as the most common form of the condition, where the exact cause is unknown. As awareness and diagnosis improve, more patients are identified with idiopathic gastroparesis, leading to an increased demand for effective treatment options to manage its chronic symptoms. Pharmaceutical companies are therefore focusing on developing therapies that target the underlying mechanisms of idiopathic gastroparesis, such as gastric dysmotility and impaired stomach emptying. This emphasis reflects a growing need for tailored treatments that address the specific challenges of this patient population.

Between 2024 and 2032, the North America gastroparesis drugs market will exhibit a strong CAGR. A higher prevalence of gastroparesis among the population is driven partly by lifestyle factors and an aging demographic. Additionally, advanced healthcare infrastructure and robust diagnostic capabilities in the region ensure early detection and treatment initiation, boosting demand. Pharmaceutical companies in North America are also at the forefront of research and development, continually innovating to meet the evolving needs of patients. These dynamics collectively contribute to the market growth in North America, making it a pivotal region for market expansion.

Table of Contents

182 Pages
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 360° synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising incidence of gastroparesis
3.2.1.2 Growing patient preference for non-invasive treatment
3.2.1.3 Rising awareness and diagnosis rate
3.2.2 Industry pitfalls & challenges
3.2.2.1 Availability of limited treatment options
3.2.2.2 Regulatory challenges
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Future market trends
3.7 Porter’s analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Company positioning matrix
4.6 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Prokinetic agents
5.3 Antiemetic drugs
5.4 Proton pump inhibitors
5.5 Other drug classes
Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Diabetes gastroparesis
6.3 Idiopathic gastroparesis
6.4 Post-surgical gastroparesis
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Injectable
7.4 Other routes of administration
Chapter 8 Market Estimates and Forecast, By Drug Type, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 OTC drugs
8.3 Prescription drugs
Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 Hospital pharmacies
9.3 Retail pharmacies
9.4 Online pharmacies
Chapter 10 Market Estimates and Forecast, By Region, 2021– 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 The Netherlands
10.3.7 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 Abbott Laboratories
11.2 AbbVie Inc,
11.3 AstraZeneca PLC
11.4 Bayer AG
11.5 Cipla Ltd.
11.6 Evoke Pharma
11.7 Pfizer Inc.
11.8 Salix Pharmaceuticals
11.9 Takeda Pharmaceutical Inc.
11.10 Teva Pharmaceutical Inc.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us